Standard coagulation assays alone are not sufficient to exclude surgically relevant rivaroxaban plasma concentrations by Kaserer, Alexander et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2019
Standard coagulation assays alone are not sufficient to exclude surgically
relevant rivaroxaban plasma concentrations
Kaserer, Alexander ; Schedler, Andreas ; Seifert, Burkhardt ; Spahn, Donat R ; Studt, Jan-Dirk ; Stein,
Philipp
Abstract: Background While mainly larger hospitals have introduced routine anti-Xa assays for rivarox-
aban (RXA), these are not readily available to smaller hospitals often relying on routine coagulation
tests such as prothrombin time (PT) and activated partial thromboplastin time (aPTT). The aim of our
study was to investigate the effect of RXA plasma concentration on the standard coagulation tests PT
(Quick test and INR) and aPTT in a large group of real-life patients. We further assessed whether nor-
mal results of these standard coagulation assays are sufficient to exclude surgically relevant RXA plasma
concentration, defined as > 50 mcg/l. Methods This retrospective study included all patients between
2012 and 2016 where anti-Xa (calibrated for RXA), PT (Quick test and INR), and/or aPTT were deter-
mined from the same sample. PT is expressed as Quick value (% of normal plasma pool). In total, 1027
measurements in 622 patients were eligible for analysis: 752 measurements of 505 patients for Quick/INR
and 594 measurements of 417 patients for aPTT. Results A moderate correlation of PT/Quick (Pearson’s
correlation coefficient − 0.59; p < 0.001), INR (Pearson’s correlation coefficient 0.5; p < 0.001), and
aPTT (Pearson’s correlation coefficient 0.53; p < 0.001) with RXA plasma concentration was observed.
However, in 50% of all samples with a normal PT/Quick, in 25% of all samples with a normal INR and
in 80% of all samples with a normal aPTT residual RXA plasma concentration was surgically relevant.
Conclusion Although a moderate correlation of RXA plasma concentration with PT/Quick, INR, and
aPTT was observed, standard coagulation assays are not sufficient to exclude surgically relevant RXA
plasma concentrations.
DOI: https://doi.org/10.1186/s13741-019-0128-9
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-177168
Journal Article
Published Version
 
 
The following work is licensed under a Creative Commons: Attribution 4.0 International (CC BY 4.0)
License.
Originally published at:
Kaserer, Alexander; Schedler, Andreas; Seifert, Burkhardt; Spahn, Donat R; Studt, Jan-Dirk; Stein,
Philipp (2019). Standard coagulation assays alone are not sufficient to exclude surgically relevant ri-
varoxaban plasma concentrations. Perioperative Medicine, 8:15.
DOI: https://doi.org/10.1186/s13741-019-0128-9
2
RESEARCH Open Access
Standard coagulation assays alone are not
sufficient to exclude surgically relevant
rivaroxaban plasma concentrations
Alexander Kaserer1* , Andreas Schedler1, Burkhardt Seifert2, Donat R. Spahn1, Jan-Dirk Studt3 and Philipp Stein1
Abstract
Background: While mainly larger hospitals have introduced routine anti-Xa assays for rivaroxaban (RXA), these are
not readily available to smaller hospitals often relying on routine coagulation tests such as prothrombin time (PT)
and activated partial thromboplastin time (aPTT).
The aim of our study was to investigate the effect of RXA plasma concentration on the standard coagulation tests
PT (Quick test and INR) and aPTT in a large group of real-life patients. We further assessed whether normal results
of these standard coagulation assays are sufficient to exclude surgically relevant RXA plasma concentration, defined
as > 50 mcg/l.
Methods: This retrospective study included all patients between 2012 and 2016 where anti-Xa (calibrated for RXA),
PT (Quick test and INR), and/or aPTT were determined from the same sample. PT is expressed as Quick value (% of
normal plasma pool). In total, 1027 measurements in 622 patients were eligible for analysis: 752 measurements of
505 patients for Quick/INR and 594 measurements of 417 patients for aPTT.
Results: A moderate correlation of PT/Quick (Pearson's correlation coefficient − 0.59; p < 0.001), INR (Pearson's
correlation coefficient 0.5; p < 0.001), and aPTT (Pearson's correlation coefficient 0.53; p < 0.001) with RXA plasma
concentration was observed. However, in 50% of all samples with a normal PT/Quick, in 25% of all samples with a
normal INR and in 80% of all samples with a normal aPTT residual RXA plasma concentration was surgically
relevant.
Conclusion: Although a moderate correlation of RXA plasma concentration with PT/Quick, INR, and aPTT was
observed, standard coagulation assays are not sufficient to exclude surgically relevant RXA plasma concentrations.
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Background
Rivaroxaban (RXA) is a direct oral anticoagulant
(DOAC) which inhibits factor Xa (Xa). It is widely used
for thromboprophylaxis in orthopaedic surgery, preven-
tion of systemic embolism in non-valvular atrial fibrilla-
tion, and treatment and secondary prevention of
venous thromboembolism (Swissmedicinfo.ch 2017). In
many patients admitted for elective and non-elective
surgery, a surgically relevant residual RXA plasma con-
centration is observed, defined as > 50 mcg/l. This is
especially important in an emergency setting (e.g.,
trauma) since it may affect patient management or be
prohibitive for surgery.
For determining RXA plasma concentration, high-
performance liquid chromatography-mass spectrometry
(HPLC-MS) is considered the gold standard (Asmis
et al. 2012). However, this method is time-consuming,
expensive, and therefore not suitable for routine clinical
use. In comparison, chromogenic anti-Xa assays cali-
brated for RXA are fast, affordable, and show a very
good agreement with HPLC-MS (Studt et al. 2017).
While most university hospitals or other large hospitals
have introduced anti-Xa assays for RXA, these are not
readily available to smaller hospitals often relying on
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routine coagulation tests such as prothrombin time (PT)
and activated partial thromboplastin time (aPTT). In
German-speaking countries, a plasma sample’s tissue
factor-induced coagulation time is typically expressed as
Quick value (%) in relation to that of a normal plasma
pool; the longer the PT, the lower the Quick value (%).
The aim of our study was to investigate the effect of
RXA plasma concentration as determined by anti-Xa
assay on the standard coagulation tests PT (Quick test
and INR) and aPTT. Further, we assessed whether
normal values of these standard coagulation assays are
sufficient to exclude surgically relevant RXA plasma
concentration which was defined as > 50 mcg/l in a large
group of real-life patients.
Material and methods
This study was approved by the local ethics committee
(Kantonale Ethikkomission Zurich, Switzerland, KEK-
ZH-No: 2017-00164).
Study design
This retrospective single-center study included all adult
patients between 2012 and 2016 where anti-Xa (cali-
brated for RXA), PT (Quick test and INR), and/or aPTT
were determined from the same plasma sample.
Patients with a RXA concentration below the assay’s
limit of quantification (20 mcg/l), without documented
RXA intake, without sufficient documentation, or with
concomitant treatment by heparin or other anticoagulants
were excluded. In total, 1027 measurements in 622
patients were eligible for investigation (Fig. 1).
Study goals
Our study aimed to investigate the impact of anti-Xa
determined RXA plasma concentration as determined by
anti-Xa assay on the standard coagulation tests PT
(Quick test and INR) and aPTT. Moreover, we assessed
in a large group of real-life patients if normal values of
these standard assays were sufficient to exclude a surgi-
cally relevant RXA plasma concentration.
Sample preparation and coagulation assays
Venous blood was drawn into tubes containing 0.109 M
sodium citrate (BD Vacutainer, Plymouth, UK). Samples
were transported immediately to the ISO 17025 accre-
dited hemostasis laboratory of the University Hospital
Zürich where all coagulation assays were performed.
RXA plasma concentration was determined by chromo-
genic anti-Xa assay calibrated for RXA (Studt et al. 2017).
During the daytime, the DiXaI assay (Hyphen Biomed,
Neuville-sur-Oise, France) was used due to its insensitivity
to heparin and at all other times a routine anti-Xa assay
(Biophen Heparin LRT, Hyphen Biomed) with the same
set of calibrators. Regular internal and external quality
control was performed for both assays, and their agree-
ment was confirmed repetitively.
Fig. 1 Flowchart showing the number of included and excluded patients for each standard coagulation assay. Not all patients had a concomitant
Quick/INR and aPTT measurement, explaining the different counts in the Quick/INR and aPTT groups. RXA = rivaroxaban, INR=international
normalized ratio, aPTT = activated partial thromboplastin time, Quick = prothrombin time expressed as % of the normal plasma pool
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In German-speaking countries, the tissue factor-induced
coagulation time is traditionally expressed as Quick (%)
instead of PT (s); therefore, PT is presented here as Quick
(%) and INR. PT (Quick test) was determined using
Innovin as thromboplastin reagent, and aPTT using the
Actin FS reagent (both Siemens Healthcare, Marburg,
Germany). Coagulometers were Siemens BCS XP and CS-
5100. Normal values for standard coagulation assays were
Quick > 70%, INR < 1.2, and aPTT 24–36 s.
Variables and data collection
Medical records were reviewed of all patients where
RXA plasma concentration was determined between
2012 and 2016. Age, sex, indication for anticoagulation,
RXA dosage, body mass index (BMI), creatinine serum
level, and glomerular filtration rate (GFR) according to
CKD-EPI formula were extracted from the hospital’s
database. The results of standard coagulation assays
(Quick, INR, aPTT) originating from those samples in
which RXA plasma concentration had been determined
were extracted from the hospital’s laboratory informa-
tion system. Data were transferred to a spreadsheet for
evaluation (Excel 2016, Microsoft Corporation, Red-
mond, USA).
Statistical analyses
Categorical data are reported as frequency (n) and per-
cent (%) and numerical data as mean and standard
deviation (SD) or median [IQR]. Due to the skew distri-
bution of RXA plasma concentrations, INR and aPTT
were logarithmically transformed. Correlation of RXA
plasma concentrations with each of the standard coagu-
lation assays was investigated using Pearson’s correlation
coefficient. A receiver operating characteristic (ROC)
curve analysis was performed calculating the area under
the curve (AUC) for each standard coagulation assay.
Statistical significance was set as a two-tailed p value of
less than 0.05. All statistical analyses were performed
with IBM SPSS Statistics (IBM SPSS Statistics v25.0.,
Armonk, NY: IBM Corp.).
Results
Patient characteristics
Patients were 58% male and 42% female, with a mean
age of 69 ± 16 years. Renal function was mildly im-
paired with a mean GFR of 68 ± 27 ml/min and mean
serum creatinine of 103 ± 63 mcmol/l. Indications for
anticoagulation included atrial fibrillation, pulmonary
embolism, deep vein thrombosis, and thromboprophy-
laxis. The most frequent RXA dose was 20 mg/day. The
mean values of standard coagulation assays (PT/Quick,
aPTT) were within the normal range (PT/Quick 70–
120%; aPTT 24–36 s), and INR was slightly increased
(Table 1).
PT/Quick and INR
Correlation of PT/Quick and RXA plasma concentra-
tion was moderate (Pearson's correlation coefficient −
0.59, p < 0.001; Fig. 2). Nevertheless, in 50% of all sam-
ples with a normal PT/Quick, the residual RXA plasma
concentration was still elevated to a surgically relevant
level > 50 mcg/l, up to a maximum of 407 mcg/l (AUC:
0.74, 95% CI 0.71 to 0.78, p < 0.001) (Table 2).
Similarly, the correlation of INR with RXA plasma
concentration was only moderate (Pearson's correlation
coefficient 0.5, p < 0.001; Fig. 3). Again, 25% of all patients
with INR < 1.2 had a surgically relevant residual RXA
plasma concentration up to a maximum of 268 mcg/l
(AUC 0.74, 95% CI 0.70 to 0.77, p < 0.001) (Table 2).
aPTT
APTT showed as well a moderate correlation with RXA
plasma concentration (Pearson's correlation coefficient
0.53, p < 0.001; Fig. 4). As many as 80% of all patients with
a normal aPTT (< 36 s) had a surgically relevant RXA
plasma concentration up to a maximum of 437 mcg/l
(AUC 0.75, 95% CI 0.71 to 0.79, p < 0.001) (Table 2).
Discussion
An increasing number of patients admitted to the emer-
gency department are anticoagulated with DOACs such
as RXA. If such information is lacking—e.g., because of
an unconscious patient—significant bleeding during
Table 1 Overview
Age (years), mean ± SD 69 ±16
Sex male, n (%) 595 (58%)
Height (cm), mean ± SD 170 ± 10
Weight (kg), mean ± SD 76 ± 18
BMI (kg/m2), mean ± SD 26 ± 5
Serum creatinine (mmol/l), mean ± SD 103 ± 63
GFR CKD-EPI (ml/min), mean ± SD 68 ± 27
Indication for RXA, n (%) Atrial fibrillation 574 (56%)
Pulmonary embolism 128 (13%)
Thrombosis 168 (16%)
Prophylaxis 83 (8%)
Other 74 (7%)
RXA dose (mg/day)
(n = 1020)
n (%)
10 69 (7%)
15 200 (20%)
20 712 (69%)
30 38 (4%)
40 1 (0%)
Quick (%), mean ± SD; median [IQR] 76 ± 23; 77 [74–79]
INR, mean ± SD, median [IQR] 1.3 ± 0.6; 1.2 [1.2–1.3]
aPTT (s), mean ± SD; median [IQR] 30 ± 12; 28 [28–29]
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invasive procedures or thrombolysis may be the conse-
quence. Furthermore, factors were identified such as
renal insufficiency or amiodarone co-medication that
may result in a higher-than-expected residual RXA
concentration even if standard preoperative interrup-
tion intervals are observed (Kaserer et al. 2018). Fast and
reliable quantification of a DOAC’s plasma concentra-
tion is therefore crucial for the clinical management.
While many universities or other large hospitals have in-
troduced routine anti-Xa assays for RXA, smaller hospi-
tals often have to rely on standard coagulation assays
such as PT/Quick, INR, or aPTT. Although we observed
a statistically significant (but moderate) correlation of
the results of these standard assays with RXA plasma
concentration, these were not sufficient to exclude a sur-
gically relevant residual RXA level.
In line with our results, a close correlation of anti-Xa ac-
tivity, PT, and aPTT has been observed previously in
healthy individuals (Turkoglu 2015). APTT showed a
slight to moderate prolongation depending on the RXA
concentration (Samama et al. 2010). In an in vitro study
simulating RXA peak plasma concentrations in healthy
volunteers, the aPTT was prolonged two-fold by RXA
peak plasma levels of 389 ± 106 mcg/l to 617 ± 149 mcg/l
(Hillarp et al. 2014). Moreover, Ikeda and Tachibana
showed in patients receiving RXA for atrial fibrillation that
aPTT tends to be prolonged (Ikeda and Tachibana 2016).
The correlation of aPTT and RXA plasma level does not
only depend on the latter since there is considerable vari-
ability among laboratories and various aPTT reagents
(Samuelson et al. 2017; Samama et al. 2013). Although the
reagent used in our laboratory (Actin FS, Siemens Health-
care) is comparatively sensitive to RXA (Samama et al.
2013), aPTT was not prolonged in 80% of patients with a
residual RXA level > 50 mcg/l.
The effect of RXA plasma level on aPTT was weaker
than for PT/Quick and INR. It was shown, that RXA pro-
longs PT/Quick in a linear and concentration-dependent
manner (Samama et al. 2010). Baglin et al. demonstrated
that normal PT cannot exclude an anticoagulant effect of
DOAC, but can indicate a subtherapeutic plasma level
(Baglin 2013). Results vary according to the thromboplas-
tin reagent (Samama et al. 2010; Dale et al. 2014). Innovin
(Siemens Healtcare), which is used in our laboratory, has
an intermediate sensitivity towards RXA as compared with
other reagents, e.g., recombiplastin, neoplastin, or neoplas-
tin plus (Samama et al. 2010). The RXA plasma concen-
tration required to prolong the PT two-fold is 301 mcg/l
using neoplastin plus compared with 700 mcg/l using
Innovin (Samama et al. 2010; Perzborn et al. 2005). A sys-
tematic review of 49 articles showed that the prolongation
of PT depends on the plasma concentration of RXA, but
that the correlation was weaker above 50–100 mcg/l
(Samuelson et al. 2017).
Although a significantly elevated INR was noted in pa-
tients taking DOAC (Ofek et al. 2017), conversion of PT
Fig. 2 Correlation of rivaroxaban plasma concentration and Quick. A statistically significant correlation is observed (Pearson's correlation
coefficient − 0.59, p < 0.001; R2 linear 0.35). Quick = prothrombin time expressed as % of normal plasma pool, RXA = rivaroxaban
Table 2 Patients with normal standard coagulation assays but
residual RXA level > 50 mcg/l
RXA > 50 mcg/l RXA plasma concentration mcg/l
n % Mean SD Min Max
Quick > 70% 264 50% 77 57 20.4 407
INR < 1.2 133 25% 63 42 20.5 268
aPTT < 36 s 333 80% 100 79 20.4 437
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to INR increased the variability and resulted in reduced
RXA responsiveness (Siegal and Konkle 2014). This is
not surprising since INR was designed for the monitor-
ing of anticoagulation with vitamin K antagonists, with a
focus on the usual target range of INR 2.0–3.0. Interest-
ingly, only 25% of our patients with a normal INR (< 1.2)
had a RXA plasma concentration above 50 mcg/l which
is the lowest proportion compared to patients with nor-
mal aPTT and/or PT/Quick.
In line with the findings of our study, the Guidance
from the British Committee for Standards in Haema-
tology by Kitchen et al. concluded that PT and aPTT
cannot be used to quantify RXA plasma concentra-
tion. At most, these assays - with some but not all
reagents – may permit a crude estimation of the in-
tensity of anticoagulation (Kitchen et al. 2014). Anti-
Xa chromogenic assays should be used instead to de-
termine RXA plasma concentration (Kitchen et al.
2014; Adcock and Gosselin 2015).
Limitations
Data of our study were collected retrospectively. Never-
theless, documentation and data collection followed
Fig. 3 Correlation of rivaroxaban plasma concentration and INR. A statistically significant correlation is observed (Pearson's correlation coefficient
0.5, p < 0.001; R2 linear 0.25). INR = international normalized ratio, RXA = rivaroxaban
Fig. 4 Correlation of rivaroxaban plasma concentration and aPTT. A statistically significant correlation is observed (Pearson's correlation coefficient
0.53, p < 0.001; R2 linear 0.28). aPTT = activated partial thromboplastin time, RXA = rivaroxaban
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Good Clinical Practice guidelines, and we assume that
the data quality is high.
Conclusion
Although a moderate correlation of RXA plasma con-
centration with PT/Quick, INR and aPTT was observed,
standard coagulation assays alone are not sufficient to
exclude a surgically relevant RXA plasma concentration.
Chromogenic anti-Xa assays should be used in patients
with suspected RXA intake.
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